Showing results (61-70 of 196) with videos related to
Sort By:
Pageof 20
Pharmaceutical Statistics|July 29, 2020
Comparing Bayesian early stopping boundaries for phase II clinical trialsLiyun Jiang, Fangrong Yan, Peter F Thall, et al.Clinical Trials (London, England)|January 21, 2006
Monitoring event times in early phase clinical trials: some practical issuesPeter F Thall, Leiko H Wooten, Nizar M TannirBiometrics|October 3, 2024
ROMI: a randomized two-stage basket trial design to optimize doses for multiple indicationsShuqi Wang, Peter F Thall, Kentaro Takeda, et al.Statistics in Medicine|June 23, 2015
Optimization of multi-stage dynamic treatment regimes utilizing accumulated dataXuelin Huang, Sangbum Choi, Lu Wang, et al.Journal of Biopharmaceutical Statistics|October 14, 2006
Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerationsPeter F Thall, John D Cook, Elihu H EsteyJCO Precision Oncology|November 22, 2021
Lessons Learned From Implementing a Novel Bayesian Adaptive Dose-Finding Design in Advanced Pancreatic CancerRebecca S S Tidwell, Peter F Thall, Ying YuanBiometrics|January 13, 2021
Bayesian group sequential enrichment designs based on adaptive regression of response and survival time on baseline biomarkersYeonhee Park, Suyu Liu, Peter F Thall, et al.Biometrics|March 18, 2006
A geometric approach to comparing treatments for rapidly fatal diseasesPeter F Thall, Leiko H Wooten, Elizabeth J ShpallJournal of the Royal Statistical Society. Series C, Applied Statistics|January 30, 2023
Utility-based Bayesian personalized treatment selection for advanced breast cancerJuhee Lee, Peter F Thall, Bora Lim, et al.Contemporary Clinical Trials Communications|March 23, 2023
A platform trial approach to proof-of-concept (POC) studies in autism spectrum disorder: Autism spectrum POC initiative (ASPI)J Kyle Wathen, Shyla Jagannatha, Seth Ness, et al.Pageof 20